Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
EGLN1
REST API REST API
Homo sapiens
EGLN1 is differentially expressed in 300 experiments: 104 organism parts: bone marrow, lung, ... (102 more);, 183 disease states: normal, control, ... (181 more);, 79 cell types 414 cell lines 53 compound treatments and 74 other conditions.
Synonyms PHD2, ZMYND6, SM-20, HIFPH2, C1orf12
Orthologs EGLN1 (Gallus gallus)   EGLN1 (2 of 2) (Danio rerio)   Egln1 (Mus musculus)   egln1 (Danio rerio)   F1LY86_RAT (Rattus norvegicus)   ENSCING00000001903 (Ciona intestinalis)   Egln1 (Rattus norvegicus)   Hph (Drosophila melanogaster)   egln1 (Xenopus laevis)   EGLN1 (Bos taurus)   EGLN1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, oxidoreductase activity, protein binding, iron ion binding, oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors, metal ion binding, response to hypoxia, oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen, L-ascorbic acid binding, zinc ion binding, oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, labyrinthine layer development, heart trabecula formation, cardiac muscle tissue morphogenesis, oxygen homeostasis, ventricular septum morphogenesis, oxidation-reduction process, peptidyl-proline dioxygenase activity, negative regulation of sequence-specific DNA binding transcription factor activity
InterPro Term Oxoglutarate/Fe-dep_oxygenase, Pro_4_hyd_alph, Znf_MYND
UniProt Accession Q9GZT9, Q9NTU9
Gene-Disease Assocation ERYTHROCYTOSIS, FAMILIAL, 3; ECYT3
Search EB-eye ENSG00000135766
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (43 experiments)

Factor Value U/D Experiments
T84
2
E-GEOD-1474, E-MTAB-37
U87
2
E-GEOD-20089, E-MEXP-903
A549
2
E-GEOD-3202, E-GEOD-6013
AGS
2
E-MTAB-37, E-GEOD-15460
KG1
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-19639, E-GEOD-20081
408 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-MEXP-120, E-GEOD-4219, E-GEOD-20677, ... (41 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
macrophage
2
E-GEOD-22373, E-GEOD-5099
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
platelet
1
E-GEOD-2006
activated B-cell
1
E-MEXP-2360
skin substitute
1
E-GEOD-3204
73 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MEXP-1121, E-GEOD-16363, ... (59 experiments)

Factor Value U/D Experiments
control
4
E-GEOD-21912, E-GEOD-16363, E-GEOD-8121, E-GEOD-16728
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
Duchenne muscular dystrophy
2
E-GEOD-3307, E-GEOD-1007
Emery-Dreifuss muscular dystrophy
2
E-GEOD-3307, E-MTAB-62
glioblastoma
2
E-GEOD-4290, E-MTAB-62
prostate cancer
2
E-MTAB-62, E-GEOD-6919
177 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, ... (29 experiments)

Factor Value U/D Experiments
oligomycin
1
E-MEXP-2285
motexafin gadolinium/zinc
1
E-GEOD-2964
HMB-PP (phosphoantigen)
1
E-MEXP-1601
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
Cxcl12
1
E-GEOD-7307
47 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-21653, E-GEOD-4922

Factor Value U/D Experiments
31
1
1
E-GEOD-21653
34
2
1
E-GEOD-3494
66 years
1
1
E-GEOD-4922
32 years
1
1
E-GEOD-4922
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-GEOD-17189, E-GEOD-19348, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, E-MTAB-62 ... (5 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-26, E-GEOD-22148, E-GEOD-21887 ... (5 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-763, E-GEOD-22056, E-GEOD-3494, E-GEOD-17476, E-TABM-43, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, E-GEOD-22278, E-GEOD-10315, ... (13 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-5764, E-MEXP-2069, E-GEOD-16363, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-TABM-321

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818 ... (5 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (6 experiments)

Processing time: 0.314 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM